Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Holdings Cut by Aquatic Capital Management LLC

Aquatic Capital Management LLC reduced its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 38.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 29,261 shares of the biopharmaceutical company's stock after selling 18,008 shares during the quarter. Aquatic Capital Management LLC's holdings in Catalyst Pharmaceuticals were worth $611,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Steward Partners Investment Advisory LLC purchased a new stake in shares of Catalyst Pharmaceuticals in the 4th quarter valued at about $27,000. Farther Finance Advisors LLC increased its position in Catalyst Pharmaceuticals by 125.1% during the fourth quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company's stock worth $56,000 after buying an additional 1,495 shares during the period. Wilmington Savings Fund Society FSB purchased a new stake in Catalyst Pharmaceuticals in the fourth quarter valued at approximately $65,000. KBC Group NV boosted its holdings in shares of Catalyst Pharmaceuticals by 48.8% in the fourth quarter. KBC Group NV now owns 4,699 shares of the biopharmaceutical company's stock valued at $98,000 after acquiring an additional 1,542 shares during the period. Finally, New Vernon Capital Holdings II LLC purchased a new position in shares of Catalyst Pharmaceuticals during the fourth quarter worth approximately $122,000. 79.22% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Catalyst Pharmaceuticals

In other news, insider Gary Ingenito sold 44,904 shares of the firm's stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total transaction of $991,929.36. Following the completion of the sale, the insider now directly owns 68,873 shares in the company, valued at $1,521,404.57. This trade represents a 39.47 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Brian Elsbernd sold 62,975 shares of the firm's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $22.98, for a total value of $1,447,165.50. Following the sale, the insider now owns 188,564 shares of the company's stock, valued at approximately $4,333,200.72. This trade represents a 25.04 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 10.40% of the company's stock.

Wall Street Analysts Forecast Growth

CPRX has been the subject of several analyst reports. Baird R W upgraded Catalyst Pharmaceuticals to a "strong-buy" rating in a research note on Monday, February 3rd. Stephens reaffirmed an "overweight" rating and set a $33.00 price target on shares of Catalyst Pharmaceuticals in a research note on Thursday, February 27th. StockNews.com upgraded Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Friday, February 28th. Bank of America reissued a "buy" rating and issued a $30.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Thursday, January 9th. Finally, Robert W. Baird increased their target price on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an "outperform" rating in a research report on Monday, March 3rd. Seven equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $32.29.

Catalyst Pharmaceuticals Trading Down 4.9 %

NASDAQ:CPRX traded down $1.20 during trading hours on Tuesday, hitting $23.11. The stock had a trading volume of 736,790 shares, compared to its average volume of 1,101,476. The company has a market cap of $2.82 billion, a PE ratio of 19.48, a price-to-earnings-growth ratio of 3.31 and a beta of 0.70. The business has a 50 day simple moving average of $22.92 and a two-hundred day simple moving average of $22.35. Catalyst Pharmaceuticals, Inc. has a 1-year low of $14.47 and a 1-year high of $26.16.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.